Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib
作者： John D. Hainsworth , Jeffrey A. Sosman , David R. Spigel , Donna L. Edwards , Cara Baughman
关键词:
摘要: Purpose To evaluate the efficacy and toxicity of combined treatment with two targeted agents, an antibody against vascular endothelial growth factor (bevacizumab) epidermal receptor tyrosine kinase inhibitor (erlotinib), in patients metastatic clear-cell renal carcinoma. Patients Methods Sixty-three carcinoma were treated bevacizumab 10 mg/kg intravenously every 2 weeks erlotinib 150 mg orally daily. reevaluated after 8 treatment; who responded continued until they experienced tumor progression. Results Fifteen (25%) 59 assessable (95% CI, 16% to 37%) had objective responses treatment, additional 36 (61%) stable disease treatment. Only eight patients' (14%) progressed at this time point. The median 1-year progression-free survivals 11 months 43%, respectively. After a follow-up 15 m...
jco.org参考文章(30)
Othon Iliopoulos, William G. Kaelin, The molecular basis of von Hippel-Lindau disease. Molecular Medicine. ,vol. 3, pp. 289- 293 ,(1997) , 10.1007/BF03401807
Subbian Ananth, Bertrand Knebelmann, Wolfram Grüning, Mohanraj Dhanabal, Gerd Walz, Isaac E Stillman, Vikas P Sukhatme, None, Transforming Growth Factor β1 Is a Target for the von Hippel-Lindau Tumor Suppressor and a Critical Growth Factor for Clear Cell Renal Carcinoma Cancer Research. ,vol. 59, pp. 2210- 2216 ,(1999)
O. Iliopoulos, A. P. Levy, C. Jiang, W. G. Kaelin, M. A. Goldberg, Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein Proceedings of the National Academy of Sciences of the United States of America. ,vol. 93, pp. 10595- 10599 ,(1996) , 10.1073/PNAS.93.20.10595
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
J.R. Gnarra, K. Tory, Y. Weng, L. Schmidt, M.H. Wei, H. Li, F. Latif, S. Liu, F. Chen, F.-M. Duh, I. Lubensky, D.R. Duan, C. Florence, R. Pozzatti, M. M. Walther, N.H. Bander, H.B. Grossman, H. Brauch, S. Pomer, J.D. Brooks, W.B. Isaacs, M.I. Lerman, B. Zbar, W.M. Linehan, Mutations of the VHL tumour suppressor gene in renal carcinoma Nature Genetics. ,vol. 7, pp. 85- 90 ,(1994) , 10.1038/NG0594-85
ROBERT J. MOTZER, PAUL RUSSO, SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA The Journal of Urology. ,vol. 163, pp. 408- 417 ,(2000) , 10.1016/S0022-5347(05)67889-5
James C. Yang, Leah Haworth, Richard M. Sherry, Patrick Hwu, Douglas J. Schwartzentruber, Suzanne L. Topalian, Seth M. Steinberg, Helen X. Chen, Steven A. Rosenberg, A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer The New England Journal of Medicine. ,vol. 349, pp. 427- 434 ,(2003) , 10.1056/NEJMOA021491
Farida Latif, Kalman Tory, James Gnarra, Masahiro Yao, Fuh-Mei Duh, Mary Lou Orcutt, Thomas Stackhouse, Igor Kuzmin, William Modi, Laura Geil, Laura Schmidt, Fangwei Zhou, Hua Li, Ming Hui Wei, Fan Chen, Gladys Glenn, Peter Choyke, McClellan M Walther, Yongkai Weng, Dah-Shuhn R Duan, Michael Dean, Damjan Glavač, Frances M Richards, Paul A Crossey, Malcolm A Ferguson-Smith, Denis Le Paslier, llya Chumakov, Daniel Cohen, A Craig Chinault, Eamonn R Maher, W Marston Linehan, Berton Zbar, Michael I Lerman, Identification of the von Hippel-Lindau disease tumor suppressor gene Science. ,vol. 260, pp. 1317- 1320 ,(1993) , 10.1126/SCIENCE.8493574
E T Walpole, J P Dutcher, J Sparano, R Gucalp, A Einzig, E Paietta, N Ciobanu, K Grima, G Caliendo, G Cavasotto, P H Wiernik, Survival After Phase II Treatment of Advanced Renal Cell Carcinoma with Taxol or High-Dose Interleukin-2 Journal of Immunotherapy. ,vol. 13, pp. 275- 281 ,(1993) , 10.1097/00002371-199305000-00007
Nicole Meyer-Morse, Gabriele Bergers, Emily Bergsland, Steven Song, Douglas Hanahan, Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors Journal of Clinical Investigation. ,vol. 111, pp. 1287- 1295 ,(2003) , 10.1172/JCI17929